Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: Is chemotaxis important to tumor response?

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Palmerini, Emanuela ^a   Benassi, Maria Serena ^b   Quattrini, Irene ^b   Pazzaglia, Laura ^b   Donati, Davide ^c   Benini, Stefania ^d   Gamberi, Gabriella ^d,e   Gambarotti, Marco ^d   Picci, Piero ^b   Ferrari, Stefano ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Laboratory of Experimental Oncology   (Italy)

^c Orthopaedic Surgery   (Italy)

^d Pathology   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CXCR4; Ezrin; IGFR1; Predictive factors; Prognostic factors; Synovial sarcoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DOXORUBICIN; EPIRUBICIN; EZRIN; IFOSFAMIDE; SOMATOMEDIN C RECEPTOR; CYTOSKELETON PROTEIN; RNA; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CELL VIABILITY; CHEMOTAXIS; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SYNOVIAL SARCOMA; BIOSYNTHESIS; FORECASTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SARCOMA, SYNOVIAL; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS, TUMOR; CHEMOTAXIS; CHILD; CYTOSKELETAL PROTEINS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, IGF TYPE 1; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; RNA, NEOPLASM; SARCOMA, SYNOVIAL; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84928690685     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-014-0222-5     Document Type: Article

References (46)

1. Brennan MF, Singer S, Maki RG, O'Sullivan B. Soft tissue sarcoma. In: DeVita VT, Hellmann S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008. p. 1741-94.
2. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol. 2008;97:314-20.
3. Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumors of soft tissue and bone. Lyon, France: IARC Press; 2002.
4. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338:153-60.
5. Panagopoulos I, Mertens F, Isaksson M, Limon J, Gustafson P, Skytting B, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer. 2001;31:362-72.
6. Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115(13):2988-98.
7. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(7):92-9.
8. Lewis JJ, Antonescu CR, Leung DHY, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18:2087-94.
9. Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18:3794-803.
10. Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchère D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19:525-34.
11. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22:4040-50.
12. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627-34.
13. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-40.
14. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer. 1994;73:2506-11.
15. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112:1585-91.
16. Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246:105-13.
17. Francis P, Namlos HM, Muller C, Edén P, Fernebro J, Berner JM, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007;8:73.
18. Nagayama S, Katagiri T, Tsunoda T. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 2002;62(20):5859-66.
19. Kim RH, Li BD, Chu QD. The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma. Sarcoma. 2011;2011:593708.
20. Oda Y, Tateishi N, Matono H, Matsuura S, Yamamaoto H, Tamiya S, et al. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer. 2009;124(8):1852-9.
21. Tornkvist M, Natalishvili N, Xie Y, Girnita A, D'Arcy P, Brodin B, et al. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem Biophys Res Commun. 2008;368:793-800.
22. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res. 1999;59:3588-91.
23. Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer. 2008;50(4):752-6.
24. Lu YJ, Birdsall S, Summersgill B, Smedley D, Osin P, Fisher C, et al. Dual colour fluorescence in situ hybridization to paraffin-embedded samples to deduce the presence of the der (X) t (X;18) (p11.2;q11.2) and involvement of either the SSX1 or SSX2 gene: a diagnostic and prognostic aid for synovial sarcoma. J Pathol. 1999;187:490-6.
25. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene. 2006;25(7):1042-52.
26. Enneking WF, Spanier SS, Goodman MA. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg. 1980;62-A: 1027-30.
27. Stanelle EJ, Christison-Lagay ER, Wolden SL, Meyers PA, La Quaglia MP. Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: an institutional review. Pediatr Surg. 2013;48(4):757-63.
28. Rikhof B, De Jong S, Suurmeijer AJ, Meijer C, Van Der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol. 2009;217(4):469-82.
29. De Bruijn DR, Allander SV, Van Dijk AH, Willemse MP, Thijssen J, Van Groningen JJ, et al. The synovial-sarcoma associated SS18-SSX2 fusion protein induces epigenetic gene (de) regulation. Cancer Res. 2006;66:9474-82.
30. Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol. 2002;161(5):1587-95.
31. Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, et al. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol. 2008;216(4):428-39.
32. Sarfstein R, Pasmanik-Chor M, Yeheskel A, Edry L, Shomron N, Warman N, et al. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem. 2012;287(4):2766-76.
33. Gold KA, Kim ES, Liu D, Yuan P, Behrens C, Solis LM, et al. Prediction of survival in resected non-small cell lung cancer using a protein-expression based risk model: Implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014;20(7):1946-54.
34. Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer. 2012;48(16):3027-35.
35. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, De Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219-30.
36. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835-41.
37. Yopp AC, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, et al. CXCR4 predicts patients outcome and recurrence patters after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2012;19 Suppl 3:S339-46.
38. Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012;23(9):2327-35.
39. Fanelli MF, Chinen LT, Begnami MD, Costa Jr WL, Fregnami JH, Soares FA, et al. The influence of transforming growth factor-a, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012;61(2):153-6.
40. D'Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, et al. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets. 2012;12(6):693-702.
41. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-48.
42. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1-a)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res. 2011;17:2074-80.
43. Weng WH, Ahlén J, Aström K, Lui WO, Larsson C. Prognostic Impact of Immunohistochemical expression of ezrin in highly malignant soft tissue sarcoma. Br J Cancer. 1999;80:1809-14.
44. Skytting BT, Bauer HC, Perfekt R, Nilsson G, Larsson O. Ki-67 is strongly prognostic in synovial sarcoma: analysis based on 86 patients from the Scandinavian Sarcoma group register. Clin Cancer Res. 2005;11:6198-204.
45. Schneider-Stock R, Onnasch D, Haeckel C, Mellin W, Franke DS, Roessner A. Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Arch. 1999;435:407-12.
46. Lagarde P, Przybyl J, Brulard C, Pérot G, Pierron G, Delattre O, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013;31:608-15.